Modality
Radioligand
MOA
RAS(ON)i
Target
TROP-2
Pathway
Ferroptosis
RACeliacCLL
Development Pipeline
Preclinical
~Dec 2013
→ ~Mar 2015
Phase 1
~Jun 2015
→ ~Sep 2016
Phase 2
~Dec 2016
→ ~Mar 2018
Phase 3
Jun 2018
→ Apr 2031
Phase 3Current
NCT08274326
1,467 pts·RA
2018-06→2031-02·Terminated
NCT03795961
2,893 pts·Celiac
2022-01→2028-09·Not yet recruiting
NCT03122877
929 pts·RA
2024-05→2025-05·Active
+1 more trial
6,650 total pts2 indications
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (4)
2025-05-2510mo agoPh3 Readout· RA
2028-09-072.4y awayPh3 Readout· Celiac
2031-02-124.9y awayPh3 Readout· RA
2031-04-175.0y awayPh3 Readout· Celiac
Trial Timeline
Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3
P3
Termina…
P3
Complet…
P3
Not yet…
P3
Active
Catalysts
Ph3 Readout
2025-05-25 · 10mo ago
RA
Ph3 Readout
2028-09-07 · 2.4y away
Celiac
Ph3 Readout
2031-02-12 · 4.9y away
RA
Ph3 Readout
2031-04-17 · 5.0y away
Celiac
ActiveCompletedTerminatedNot yet recruiting|StartCompletionToday
Trials (4)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08274326 | Phase 3 | RA | Terminated | 1467 | SRI-4 |
| NCT03795961 | Phase 3 | Celiac | Not yet recr... | 2893 | UPCR |
| NCT03122877 | Phase 3 | RA | Active | 929 | NT-proBNP |
| NCT04947625 | Phase 3 | Celiac | Completed | 1361 | SRI-4 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| NVS-4076 | Novartis | Preclinical | TROP-2 | |
| NVS-8902 | Novartis | Preclinical | TROP-2 | |
| MRK-6781 | Merck & Co | Approved | TIGIT | |
| SNY-9073 | Sanofi | Phase 2 | B7-H3 | |
| Zanumavacamten | GSK | Phase 2/3 | TROP-2 | |
| Tixarelsin | Vertex Pharma | Phase 1 | ALK | |
| Fixatuximab | Legend Biotech | Preclinical | CFTR | |
| ION-1378 | Ionis | NDA/BLA | TROP-2 | |
| Nirafotisoran | Jazz Pharma | Phase 2/3 | TROP-2 | |
| 180-3597 | Innovent Bio | Preclinical | SHP2 |